Upgrade to SI Premium - Free Trial

BioLineRx (BLRX)

2.43 -0.08 (3.19%)

Chart
Today 6M 1Y 5Y

Upcoming Events

- Earnings (8/14/26 *Est.)

Latest Headlines

BioLineRx and Hemispherian to present GLIX1 data at EANO 2026 September 10, 2026 7:00 AM - StreetInsider Form 6-K BioLineRx Ltd. For: Sep 10 September 10, 2026 7:00 AM - SEC Filing BioLineRx and Hemispherian AS to Present Encouraging GLIX1 Preclinical Efficacy Data and its Phase 1/2a Trial Design at the 21st Meeting of the European Association of Neuro-Oncology (EANO 2026) September 10, 2026 7:00 AM - PR NewsWire Form 6-K BioLineRx Ltd. For: Aug 28 August 28, 2026 8:12 AM - SEC Filing BioLineRx plans $3.75M share offering at $2.78 per ADS August 28, 2026 8:00 AM - StreetInsider BioLineRx Announces $3.75 Million Registered Direct Offering and Concurrent Private Placement August 28, 2026 8:00 AM - PR NewsWire BioLineRx to Report Second Quarter 2026 Results on August 31, 2026 August 25, 2026 7:00 AM - PR NewsWire Form 6-K BioLineRx Ltd. For: Aug 18 August 18, 2026 4:04 PM - SEC Filing BioLineRx and Hemispherian to present GLIX1 ovarian cancer data at ESMO July 20, 2026 7:02 AM - StreetInsider BioLineRx and Hemispherian AS to Present Data Demonstrating Strong Synergy of GLIX1 with PARP Inhibitors in HR-Proficient Ovarian Cancers at ESMO 2026 July 20, 2026 7:00 AM - PR NewsWire Form 6-K BioLineRx Ltd. For: Jul 08 July 8, 2026 7:08 AM - SEC Filing BioLineRx and Hemispherian report GLIX1 and olaparib synergy in ovarian cancer July 8, 2026 7:00 AM - StreetInsider BioLineRx and Hemispherian Announce New Preclinical Data Demonstrating Strong Synergistic Effect between GLIX1 and PARP Inhibitor in a Patient-Derived Ovarian Cancer Xenograft Model July 8, 2026 7:00 AM - PR NewsWire Full Article List